Ozempic Gastroparesis Attorney: Understanding Florida's Statute of Limitations

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Exposure Concerns

For decades, public health communication has centered on general wellness and the broad dissemination of scientific knowledge, empowering individuals to make informed decisions about their well-being. This legacy of accessible health information has laid a foundation for understanding how medical interventions can carry unintended consequences, particularly when new treatments enter widespread use. As the landscape of chronic disease management evolves, so too does the public’s need to connect general health awareness with specific, real-world exposures. One such area of growing attention involves the use of glucagon-like peptide-1 receptor agonists, originally developed for metabolic conditions, and their potential association with delayed gastric emptying. This concern has prompted individuals to examine not only the clinical outcomes but also the legal and regulatory frameworks surrounding these medications. In Florida, where statutes of limitations impose strict deadlines for filing claims, those who have used Ozempic and subsequently developed gastroparesis must navigate a complex intersection of medical history and legal accountability. The transition from a general health context to this specific exposure scenario requires careful consideration of how long-standing principles of informed consent and product liability apply to emerging pharmaceutical risks. By bridging the gap between broad health literacy and targeted legal recourse, stakeholders can better address the implications of occupational and therapeutic exposure in a rapidly changing medical environment.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action involves slowing gastric emptying, which contributes to glycemic control but also raises concerns about gastrointestinal adverse effects, including gastroparesis. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, and it requires exclusion of other causes. The prescribing information for Ozempic documents a significantly higher incidence of gastrointestinal adverse reactions compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Nausea was reported in 6.1% of placebo patients, 15.8% of Ozempic 0.5 mg patients, and 20.3% of Ozempic 1 mg patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Vomiting occurred in 2.3%, 5.0%, and 9.2% of patients, respectively, and diarrhea in 1.9%, 8.5%, and 8.8% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Abdominal pain was reported in 4.6%, 7.3%, and 5.7% of patients, and constipation in 1.5%, 5.0%, and 3.1% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with frequencies below 5% included dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

The Link Between Ozempic and Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves GLP-1 receptor activation, which inhibits gastric motility and delays gastric emptying. This effect is dose-dependent and can become clinically significant, leading to symptoms consistent with gastroparesis. While the prescribing information lists nausea, vomiting, and abdominal pain as common adverse reactions, it does not explicitly mention gastroparesis as a distinct adverse event. This raises questions about the adequacy of warnings for patients who may develop severe or persistent symptoms. The label notes that gastrointestinal adverse reactions are most frequent during dose escalation, but it does not provide specific guidance on monitoring for gastroparesis or when to discontinue therapy if symptoms suggest delayed gastric emptying. For patients in Florida who have developed gastroparesis after using Ozempic, attorney-related considerations include the statute of limitations for filing a product liability claim. In Florida, the statute of limitations for personal injury claims, including those related to defective drugs, is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is critical because gastroparesis symptoms may develop gradually, and patients might not immediately connect their condition to Ozempic use. The timeline between exposure to Ozempic and documented harm can vary. Some patients experience symptoms during dose escalation, while others may develop gastroparesis after months or years of use. Medical records documenting the onset of symptoms, diagnostic tests confirming gastroparesis, and a temporal relationship to Ozempic use are essential for establishing a claim. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to evaluate the strength of their case, including whether the manufacturer provided adequate warnings about the risk of gastroparesis. The prescribing information does not list gastroparesis as a specific adverse reaction, which may be relevant to claims of inadequate warning. Additionally, patients should be aware that the statute of limitations may begin when they first experienced symptoms that a reasonable person would associate with the drug, not necessarily when a formal diagnosis is made. Prompt legal consultation is advisable to preserve the right to seek compensation for medical expenses, lost wages, and pain and suffering.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Florida?

In Florida, the statute of limitations for personal injury claims, including product liability cases related to Ozempic, is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. This means that if you developed gastroparesis after using Ozempic, you typically have four years from when you first became aware of the connection to file a lawsuit. However, because symptoms may develop gradually, it is important to consult an attorney promptly to ensure your claim is timely.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is known to slow gastric emptying as part of its mechanism of action. Clinical trials have shown a significantly higher incidence of gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the prescribing information does not explicitly list gastroparesis as a distinct adverse event, the drug's effect on gastric motility can lead to symptoms consistent with gastroparesis. Patients who experience persistent gastrointestinal symptoms should discuss the possibility of gastroparesis with their healthcare provider.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.